MacroGenics, Inc. (MGNX) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of MacroGenics, Inc. (NASDAQ:MGNX) from a sell rating to a hold rating in a report issued on Tuesday.

According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “

A number of other analysts have also weighed in on the company. Stifel Nicolaus reissued a buy rating and set a $34.00 price objective on shares of MacroGenics in a research note on Tuesday, September 12th. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $26.00 price target on shares of MacroGenics in a research note on Friday, September 1st. ValuEngine raised MacroGenics from a strong sell rating to a sell rating in a research note on Friday, September 1st. BidaskClub lowered MacroGenics from a hold rating to a sell rating in a research note on Monday, July 31st. Finally, Wedbush reaffirmed an outperform rating and issued a $44.00 price target on shares of MacroGenics in a research note on Monday, September 11th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $30.30.

MacroGenics (NASDAQ:MGNX) traded down 0.57% during trading on Tuesday, reaching $17.42. 29,330 shares of the company were exchanged. MacroGenics has a one year low of $14.36 and a one year high of $31.85. The firm’s 50 day moving average price is $17.79 and its 200-day moving average price is $18.17. The stock’s market capitalization is $641.02 million.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.09). The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $15.82 million. MacroGenics had a negative net margin of 1,216.51% and a negative return on equity of 56.81%. The business’s revenue for the quarter was down 97.9% compared to the same quarter last year. During the same period last year, the company posted $1.12 EPS. On average, equities research analysts predict that MacroGenics will post ($4.42) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/10/13/macrogenics-inc-mgnx-raised-to-hold-at-zacks-investment-research.html.

Hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new stake in MacroGenics in the second quarter worth $133,000. Legal & General Group Plc lifted its stake in MacroGenics by 4.3% in the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 328 shares during the period. SG Americas Securities LLC lifted its stake in MacroGenics by 92.2% in the second quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 5,187 shares during the period. Parametric Portfolio Associates LLC purchased a new stake in MacroGenics in the second quarter worth $203,000. Finally, Virtu KCG Holdings LLC purchased a new stake in MacroGenics in the second quarter worth $232,000. 84.47% of the stock is owned by institutional investors.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Get a free copy of the Zacks research report on MacroGenics (MGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply